Public reporting on pharmaceutical industry-led access programs: Alignment with the WHO medicine programs evaluation checklist

dc.contributor.author	Laing, Richard O.
dc.contributor.author	Umeh, Chukwuemeka Anthony
dc.contributor.author	Rockers, Peter C.
dc.date.accessioned	2020-12-15T08:10:50Z
dc.date.available	2020-12-15T08:10:50Z
dc.date.issued	2020
dc.identifier.citation	10. Laing, R. O. et al. (2020). Public reporting on pharmaceutical industry-led access programs: Alignment with the WHO medicine programs evaluation checklist. Journal of Pharmaceutical Policy and Practice ,13(1),5	en_US
dc.identifier.issn	2052-3211
dc.identifier.uri	https://doi.org/10.1186/s40545-020-0204-z
dc.identifier.uri	http://hdl.handle.net/10566/5515
dc.description.abstract	There has been increased demand for greater public accountability and transparency of private sector-led global health partnership programs. This study critically reviews and pilot tests the World Health Organization (WHO) medicine program checklist as a framework for public reporting and assessing of programs.	en_US
dc.language.iso	en	en_US
dc.publisher	Springer Nature	en_US
dc.subject	Medicines	en_US
dc.subject	Access	en_US
dc.subject	Industry	en_US
dc.subject	Private sector	en_US
dc.subject	Transparency	en_US
dc.title	Public reporting on pharmaceutical industry-led access programs: Alignment with the WHO medicine programs evaluation checklist	en_US
dc.type	Article	en_US